MarketPeel
Insider Trading Intelligence
Pricing
…
DW

David O. Watson

APLS
GENERAL COUNSEL · APELLIS PHARMACEUTICALS, INC. · CIK 0001657719
FILING MIX · LIFETIME34%/66%
BUYS
44
SELLS
87
TOTAL VALUE
$12.86M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
28,508
AVG SELL PX
$36.38
TRADE KIND
SHOWING 131 / 131
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
34 backtested trades · 8 horizons · 27 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by David O. Watson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d34+38.24%+1.12%+0.62%+0.50%+1.08%0.58
14d34+44.12%+0.48%+0.79%-0.30%+2.13%-0.22
30d34+61.76%-3.61%-0.25%-3.36%-4.71%-1.44
60d34+79.41%-7.01%+0.83%-7.84%-13.69%-2.73
90d34+58.82%+2.86%+2.32%+0.54%-12.36%0.09
180d34(3 pending)+53.33%-0.33%+6.00%-6.23%+2.11%-0.97
1y34(10 pending)+65.22%-9.69%+16.17%-25.46%-45.08%—
2y34(14 pending)+30.00%-10.69%+23.90%-34.58%-11.54%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
APLS · 28,508 shares · as of May 14, 2026
043,94887,897131,845175,793202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 44 buys / 87 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
32,072——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
38,250——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
37,708——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
10,000——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
41,250——41,250May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
34,533——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
82,500——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
27,993——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
50,974——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
50,136——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
11,874——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
45,000——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
7,363——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
41,250——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
144,517——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
14,000——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
28,508——28,508May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
28,508——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
6,001——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
55,986——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
55,986——55,986May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
27,993——27,993May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
55,986——144,517Jan 28, 2026Jan 30, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
7,832$21.77$170.5K88,531Jan 22, 2026Jan 23, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,475$19.79$49.0K96,363Jan 20, 2026Jan 21, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,780$22.19$128.2K98,838Jan 13, 2026Jan 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
888——14,000Jan 7, 2026Jan 9, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
888$14.95$13.3K104,618Jan 7, 2026Jan 9, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$24.49$122.5K103,730Dec 16, 2025Dec 18, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$20.06$100.3K108,730Nov 17, 2025Nov 18, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$25.22$126.1K113,730Oct 16, 2025Oct 17, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$24.34$121.7K118,730Sep 16, 2025Sep 18, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
20,000$26.17$523.4K50,136Sep 10, 2025Sep 12, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$27.80$139.0K123,730Aug 18, 2025Aug 19, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$19.55$97.8K128,730Jul 16, 2025Jul 18, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,000$18.77$93.8K133,730Jun 16, 2025Jun 17, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
82,500$19.39$1.60M82,500Jun 9, 2025Jun 11, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,569$25.10$139.8K138,730Mar 5, 2025Mar 6, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
6,667——10,000Mar 4, 2025Mar 6, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
6,667——0Mar 4, 2025Mar 6, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
695$29.52$20.5K144,299Jan 29, 2025Jan 30, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
3,323$30.43$101.1K144,994Jan 22, 2025Jan 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
42,762——148,317Jan 21, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,201$29.96$65.9K105,555Jan 17, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
4,965$28.70$142.5K107,756Jan 13, 2025Jan 14, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,000$34.24$171.2K112,721Dec 11, 2024Dec 13, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
10,569——70,136Sep 27, 2024Sep 30, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
10,569——117,721Sep 27, 2024Sep 30, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
3,762——0Mar 6, 2024Mar 8, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
3,762$13.85$52.1K107,152Mar 6, 2024Mar 8, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
781$67.77$52.9K103,390Feb 12, 2024Feb 13, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
906$64.14$58.1K104,171Jan 29, 2024Jan 31, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
4,184$65.00$271.9K105,077Jan 22, 2024Jan 23, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
4,240$66.81$283.3K109,261Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,533$66.30$2.29M34,533Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
23,748——113,501Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
1,605$57.00$91.5K92,053Dec 19, 2023Dec 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,300$57.38$132.0K89,753Dec 19, 2023Dec 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
7,905——3,762Dec 19, 2023Dec 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
7,905$13.85$109.5K93,658Dec 19, 2023Dec 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
12,750——80,705Jun 28, 2023Jun 29, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
12,750——94,263Jun 28, 2023Jun 29, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
67,955——107,013Apr 21, 2023Apr 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
67,955——67,955Apr 21, 2023Apr 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,886——175,793Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,023——14,023Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
825$58.50$48.3K174,968Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
532$51.21$27.2K165,907Feb 10, 2023Feb 14, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
551$52.77$29.1K166,439Jan 27, 2023Jan 30, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,034$52.05$105.9K166,990Jan 20, 2023Jan 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
29,452——169,024Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
37,708$52.66$1.99M37,708Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
24,003——139,572Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
10,000$44.51$445.1K115,569Jun 22, 2022Jun 23, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,000$50.00$250.0K125,569Apr 25, 2022Apr 26, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
1,875——130,569Apr 21, 2022Apr 26, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
11,250——0Apr 21, 2022Apr 26, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
491$47.12$23.1K132,444Feb 10, 2022Feb 14, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
650$38.59$25.1K132,935Jan 28, 2022Jan 31, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
36,951——36,951Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
26,051——133,585Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
1,200$48.50$58.2K107,534Dec 27, 2021Dec 28, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
4,715$14.95$70.5K108,734Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
300$48.58$14.6K108,734Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
4,826$13.85$66.8K109,193Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
4,715——20,285Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,174——16,493Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
4,826——11,667Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,097$47.86$243.9K109,034Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
5,397$14.95$80.7K114,131Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,397——14,888Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
5,174$13.85$71.7K104,367Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,174$47.72$246.9K104,019Dec 22, 2021Dec 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
954$4.31$4.1K99,193Sep 10, 2021Sep 13, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
954——0Sep 10, 2021Sep 13, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
489——954Jun 21, 2021Jun 22, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
489$4.31$2.1K98,239Jun 21, 2021Jun 22, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
489——1,443May 28, 2021Jun 1, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
489$4.31$2.1K97,750May 28, 2021Jun 1, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
489$4.31$2.1K97,261Apr 22, 2021Apr 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
489——1,932Apr 22, 2021Apr 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
978——2,421Mar 22, 2021Mar 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
978$4.31$4.2K96,772Mar 22, 2021Mar 23, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
468$47.72$22.3K95,794Feb 10, 2021Feb 11, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,875——96,262Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,500——94,387Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,250——11,250Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
23,441——0Jan 27, 2021Jan 28, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
20,042$4.31$86.4K86,887Jan 27, 2021Jan 28, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
20,042——3,399Jan 27, 2021Jan 28, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
23,441$3.76$88.1K66,845Jan 27, 2021Jan 28, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
900$53.86$48.5K44,504Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,709$50.61$137.1K49,093Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
8,398$13.85$116.3K51,802Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
1,163$52.73$61.3K45,404Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
200$55.91$11.2K43,404Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
900$55.00$49.5K43,604Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
2,526$51.32$129.6K46,567Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
8,398——21,667Dec 14, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
9,935$13.85$137.6K53,339Dec 11, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
9,935——30,065Dec 11, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
9,935$50.00$496.8K43,404Dec 11, 2020Dec 15, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
38,250——38,250Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
5,000$44.50$222.5K35,417Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
7,505$2.67$20.0K42,922Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,375——40,417Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
7,505——0Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
15,000——7,505Jan 27, 2020Jan 28, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
General Counsel
3,000$40.47$121.4K19,042Jan 27, 2020Jan 28, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
General Counsel
15,000$2.67$40.0K34,042Jan 27, 2020Jan 28, 2020 ↗View →
Other insiders · APLS
Loading peer insiders…
About this filer
CIK 0001657719
ROLE
General Counsel
PRIMARY
APLS
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001657719DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback